<DOC>
	<DOCNO>NCT00979329</DOCNO>
	<brief_summary>The purpose study assess influence Sunitinib Sorafenib fatigue , quality life depression patient metastatic renal cell colorectal cancer GIST . In order get insight mechanism vascular endothelial growth factor ( VEGF ) relate fatigue possible come resolution side effect .</brief_summary>
	<brief_title>Study Influence Sunitinib Sorafenib Fatigue , QoL , Depression Patients With Metastatic RCC GIST</brief_title>
	<detailed_description>When cure longer possible , cancer patient enter palliative phase . For many type cancer several treatment option available . The goal treatment prolong survival , maintenance even improvement quality life equal importance . The currently available systemic treatment option consist conventional cytotoxic therapy , hormonal therapy , immunotherapy so-called targeted therapy . Combinations therapy also use . Targeted therapy concern application new class drug specifically direct one well-defined molecular target relevant carcinogenesis , cell cycle regulation , tumour progression , metastasis , tumour angiogenesis and/or apoptosis . Today , successful drug class direct vascular endothelial growth factor ( VEGF ) epidermal growth factor receptor ( EGFR ) . There explosive development ongoing field many new drug become available new target inhibit combination target . Meanwhile , target therapy show efficacy many type cancer register several indication . The toxicity profile target therapy still largely unknown , aetiology many know side effect clarify . This imply effective treatment side effect early phase development . Given impact side effect quality life patient , increase knowledge topic urgently require . Currently systematic study available address issue . At moment , three target therapy direct VEGF register used Netherlands : Sunitinib ( Sutent® ) Sorafenib ( Nexavar ® ) oral drug Bevacizumab ( Avastin® ) , intravenously drug . In study focus fatigue , quality life depression patient metastatic cancer , treat Sunitinib Sorafenib . Fatigue one frequent side effect target therapy direct VEGF huge influence quality life . The incidence fatigue patient use Sunitinib phase I study 70 % fatigue often dose limit . ( 1-4 ) In phase II-III study incidence 27 % - 51 % . 5,6 In phase III randomize , double-blind placebo-controlled trial Sorafenib incidence fatigue Sorafenib group 37 % placebo group 28 % . ( 7 ) It possible fatigue symptom depression anxiety , alternatively , prolong fatigue lead depression anxiety.8 There find significant positive correlation anxiety depressive symptom fatigue treatment cancer .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>patient metastatic renal cell GIST treatment Sunitinib Sorafenib plan Karnofsky score &gt; 70 % age &gt; 18 year write informed consent questionnaire contraindication treatment Sunitinib Sorafenib patient speak write Dutch language adequately previous systemic treatment within last 7 day start study , Sunitinib , Sorafenib Bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>sorafenib</keyword>
	<keyword>fatigue</keyword>
	<keyword>depression</keyword>
	<keyword>quality life</keyword>
	<keyword>metastatic RCC</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>GIST</keyword>
</DOC>